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Characterization of porcine Hepatic 
and Intestinal Drug Metabolizing 
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Activity and Selectivity Perspective
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Mathias Devreese  1, Dieter Deforce  2, Jan Van Bocxlaer3 & siska Croubels  1
Over the past two decades, the pig has gained attention as a potential model for human drug 
metabolism. Cytochrome P450 enzymes (CYP450), a superfamily of biotransformation enzymes, are 
pivotal in drug metabolism. Porcine CYP450 has been demonstrated to convert typical substrates of 
human CYP450. Nevertheless, knowledge and insight into porcine CYP450 quantity and substrate 
selectivity is scant, especially regarding intestinal CYP450. The current study aimed to map the 
quantities of hepatic and intestinal CYP450 in the conventional pig by using a proteomic approach. 
Moreover, the selectivity of the six most common used probe substrates (phenacetin, coumarin, 
midazolam, tolbutamide, dextromethorphan, and chlorzoxazone) for drug metabolizing enzyme 
subfamilies (CYP1A, CYP2A, CYP3A, CYP2C, CYP2D and CYP2E respectively), was investigated. Hepatic 
relative quantities were 4% (CYP1A), 31% (CYP2A), 14% (CYP3A), 10% (CYP2C), 28% (CYP2D) and 13% 
(CYP2E), whereas for the intestine only duodenal CYP450 could be determined with 88% for CYP3A 
and 12% for CYP2C. Furthermore, the results indicate that coumarin (CYP2A), midazolam (CYP3A), 
tolbutamide (CYP2C), and dextromethorphan (CYP2D) are as selective for porcine as for human 
CYP450. However, phenacetin (CYP1A2) and chlorzoxazone (CYP2E1) are less selective for the specific 
enzyme, despite similarities in selectivity towards the different enzymes involved compared to humans.
Up to 55% of the available drugs in human medicine are metabolized by cytochrome P450 (CYP450) enzymes. 
These enzymes are major contributors to phase I drug metabolism and catalyze oxidative, reductive, and hydro-
lytic reactions of endogenous and xenobiotic compounds1,2. The resulting compounds are often more water solu-
ble and available for further phase II conjugation3,4. Regarding xenobiotic metabolism, members belonging to the 
CYP1, CYP2 and CYP3 family are crucial, and are responsible for 70 to 80% of CYP450 mediated drug metabo-
lism2,3,5. Hence, CYP450 biotransformation is investigated early on in the development of new drugs.
The establishment of a preclinical animal model that correlates well with humans, is a valuable tool in drug 
development and safety testing6. However, frequently used animals such as the mouse, rat and rabbit, are often not 
ideal for modelling human drug metabolism, possibly due to differences in enzyme expression and/or selectiv-
ity7–10. In the past two decades the pig has gained attention as a more appropriate animal model for humans due to 
similar anatomy and physiology11–14. In pigs, orthologues of human CYP1A2, CYP2A6, CYP3A4/5, CYP2C9/19, 
CYP2D6, and CYP2E1 have been isolated and identified with homologies in amino acid sequence, ranging from 
62 to 87.5%15. Sequence identity does not guarantee similar activity/selectivity though. Single nucleotide poly-
morphisms have been shown to significantly alter CYP450 expression, stability, and function16,17. For example, 
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recent insights in the two CYP2C9 polymorphisms show differences in side chain interaction, ultimately leading 
to different binding of the substrate losartan18.
In previous research both pigs and minipigs have been used as a model for humans. Unfortunately, very few 
studies consistently compared minipig CYP450 expression (and activity) vs. conventional pig CYP450, hence 
the use of the word ‘(mini)pig’ in the text below19–22. The detailed comparison and distinction between the two 
types of pigs is further complicated by a lack of quantitative data of pig and minipig CYP450 expression at the 
protein level. The few reports available indicate that differences in activity between conventional and minipigs 
primarily originate from differences in immunochemically quantified CYP450 enzymes19,22, stressing the impor-
tance of comparing activities from a quantitative perspective. Furthermore, CYP450 amino acid sequence in 
conventional and minipigs seems to be almost identical. Specifically there is only one amino acid difference in 
the CYP2E1 enzyme and a predicted difference of 10 amino acids between minipig CYP2D21 and conventional 
porcine CYP2D2515,23, however the latter has not been verified at the protein level.
When comparing porcine and human CYP450, three main areas of interest can be distinguished: mRNA 
expression, enzyme quantity, and CYP450 activities.
To date, mRNA expression of (mini)pig CYP450 has been determined in the liver, intestine, lung, kidney, 
heart, and even brain24–35. Although mRNA expression data can be indicative of the amount of translated protein, 
mRNA levels are not predictive for protein quantity and activity. This can be due to mRNA instability, protein 
degradation, and translational or posttranslational modifications. Consequently, direct comparison between 
mRNA amounts are of limited use36.
Cytochrome P450 proteins have usually been quantified by Western blotting, resulting in relative expressions 
of the investigated enzymes19,37,38. Although Western blotting has proven to be a valuable tool, it has the limitation 
that a selection of enzymes of interest has to be made prior to the experiments. Contrarily, a mass spectrometry 
based method does not impose such prior restrictions and allows for absolute quantification more easily. Such 
an approach was used by Achour et al. (2011) to quantify hepatic CYP450 in conventional (Suffolk White) adult 
pigs by a state-of-the-art high resolution mass spectrometry (HRMS) method39. Unfortunately, the study was 
performed on just two pigs and did not include quantification of intestinal CYP450 enzymes. Moreover, intestinal 
quantitative data are restricted to CYP1A1 and CYP3A enzymes33,40,41 of which none included the entire small 
intestine, i.e. duodenum, jejunum, and ileum. Nonetheless, this information is pivotal for in vitro-in vivo corre-
lations and to successfully determine the contribution of each enzyme to specific biotransformation reactions42.
In the past, typical probe substrates for human CYP450 have been used to measure CYP450 activity in the 
(mini)pig. Phenacetin (CYP1A), coumarin (CYP2A), midazolam (CYP3A), tolbutamide (CYP2C), dextrometho-
rphan (CYP2D), and chlorzoxazone (CYP2E) are commonly used substrates in human drug research43. These 
substrates are also metabolized by CYP450 in the (mini)pig19,20,37,44–50. Although similarities and differences in 
biotransformation rates between humans and pigs have been discussed15,51, less attention has been devoted to 
the apparent selectivity of the substrates used. It has been shown that chlorzoxazone is metabolized by porcine 
recombinant CYP2A, CYP1A, and CYP2C enzymes, although it is a typical CYP2E1 substrate47,52. Furthermore, 
it has been proposed that dextromethorphan-O-demethylation may be catalyzed by CYP2B in the pig rather than 
CYP2D20, even though no CYP2B22 was found in conventional pigs39.
Therefore, the goals of the current study were (1) to consistently map and characterize the hepatic and intes-
tinal CYP450 enzymes in 16 conventional, 12 weeks old pigs, to allow a more rational comparison between 
pigs and minipigs in future research, (2) to assess the apparent selectivity of the most commonly used probe 
substrates towards six important CYP450 enzymes for drug metabolism, which are phenacetin (CYP1A), cou-
marin (CYP2A), midazolam (CYP3A), tolbutamide (CYP2C), dextromethorphan (CYP2D), and chlorzoxazone 
(CYP2E), and 3) to compare porcine and human CYP450 with respect to substrate selectivity and activity.
Materials and Methods
Chemicals and reagents. Phenacetin (PH), acetaminophen or paracetamol (PAR), tolbutamide 
(TB), 7-hydroxy-coumarin (OH-CM), dextrorphan-D3 (DXT-D3), coumarin (CM), chlorzoxazone (CZ), 
diethyldithiocarbamate (DDC), ketoconazole (KET), α-naphthoflavone (α-NFV), 8-methoxypsoralen (8-MPS), 
protease inhibitor (cOmpleteTM Protease Inhibitor Cocktail, Roche), trifluoroacetic acid (TFA), dimethylsul-
foxide (DMSO), triethylammonium bicarbonate (TEABC), dithiotreitol (DTT), methyl methane thiosulfonate 
(MMTS), calcium chloride, and phosphate buffered saline (PBS) were purchased from Sigma Aldrich (St. Louis, 
MO, USA). Midazolam (MDZ), 1-hydroxy-midazolam (OH-MDZ), 1-hydroxy-midazolam-D4 (OH-MDZ-D4), 
4-hydroxy-tolbutamide (OH-TB), 6-hydroxy-chlorzoxazone (OH-CZ) were obtained from LGC stand-
ards (Molsheim, France). Dextromethorphan (DXM), dextrorphan tartrate (DXT), 7-hydroxycoumarin-D5 
(OH-CM-D5), acetaminophen-D4 (PAR-D4), 4-hydroxytolbutamide-D9 (OH-TB-D9), quinidine (QND) and 
sulphaphenazole (SFZ) were purchased from Toronto Research Chemicals (North York, ON, Canada). NADPH 
was obtained from OYC Europe (Rotterdam, The Netherlands). Six-hydroxy-chlorzoxazone-13C6 (OH-CZ-13C6) 
was obtained from Alsachim (Illkirch Graffenstaden, France). Potassium chloride, potassium dihydrogenphos-
phate and dipotassium hydrogenphosphate, citric acid, glycerol, disodium hydrogenphosphate, and EDTA were 
obtained from VWR (Leuven, Belgium). Acetonitrile (ACN), methanol (MeOH), ethylacetate were of HPLC 
grade and purchased from Fisher Chemicals.
Stock solutions of each substrate and inhibitor were prepared in MeOH (MDZ, 3.26 mg/mL; CM, 0.13 mg/mL; 
DXM, 6.67 mg/mL; PH, 16.14 mg/mL; KET, 0.32 mg/mL; 8-MPS, 0.43 mg/mL; QND, 0.07 mg/mL; α-NFV, 
0.06 mg/mL) or ACN (TB, 48.66 mg/mL; CZ, 15.26 mg/mL; SFZ, 0.32 mg/mL; DDC, 9.01 mg/mL)) and 
stored at −20 °C. Fresh working solutions were prepared by adding an appropriate amount of stock solution 
to HPLC-quality water. The stop reagent consisted of 55% ACN, 42% HPLC water, and 3% formic acid with 
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internal standards (final concentrations: 40 ng/mL, 100 ng/mL, 100 ng/mL, 200 ng/mL, 200 ng/mL and 40 ng/mL 
for OH-MDZ-D4, OH-CZ-13C6, OH-TB-D9, OH-CM-D5, PAR-D4 and DXT-D3 respectively).
Preparation of microsomes. Microsomes were prepared from hepatic and intestinal tissues collected from 
sixteen different conventional pigs (hybrid sow × Piétrain boars, 12 weeks of age, 8 boars and 8 sows). Pigs of this 
age were selected as most human CYP450 enzymes reach adult activity at the age of 6 years, which corresponds 
to an age of 4–12 weeks in pigs53,54. All procedures were in accordance with the ethical standards of the ethical 
committee of the Faculties of Veterinary Medicine and Bioscience Engineering of Ghent University (approval 
EC2015_213).
Fresh samples were taken from the left liver lobe, mid-duodenum, mid-jejunum and mid-ileum, rinsed in 
PBS and immediately snap frozen in liquid nitrogen and stored at −80 °C. Hepatic microsomes were prepared 
according to Wilson et al.55 and the intestinal microsomes were prepared using the mincing method described 
by Osselaere et al.56.
Briefly, liver tissues, stored for a maximum of 8 weeks, were thawed on ice in approximately 4 mL of a 0.25 M 
phosphate buffer (pH 7.25) containing 1.15% aqueous KCl (buffer A). Next, 4 grams of tissue was transferred to a 
petri dish and minced into small pieces, subsequently transferred to a Potter Elvehjem homogenizer and homog-
enized in 8 mL of buffer A. Glass tubes were rinsed twice with 4 mL of the same buffer solution and added to the 
homogenate. Samples were then centrifuged at 10,000 × g for 25 min at 4 °C. After centrifugation, the superna-
tant was transferred to ultracentrifugation tubes and centrifuged at 100,000 × g for 80 min at 4 °C. Samples were 
washed 4 times with 3 mL of buffer A solution and again centrifuged at 100,000 × g for 80 min at 4 °C. The micro-
somal pellets were suspended in 1.5 mL/g liver tissue of buffer A containing 30% glycerol, snap frozen and stored 
at −80 °C. All procedures were performed on ice.
Intestinal tissues were prepared according to an analogous procedure. Four gram of each segment was thawed on 
ice in 4 mL of thaw solution containing 1.5 mM KCl, 96 mM NaCl, 27 mM sodium citrate, 8 mM KH2PO4, 5.6 mM 
Na2HPO4 and one tablet of protease inhibitor per 50 mL of solution. After mincing, the tissues were transferred to 
a Potter Elvehjem homogenizer. Tissues were homogenized in 8 mL of homogenization buffer (50 mM phosphate 
buffer with 1 mM EDTA and 1 tablet of protease inhibitor per 50 mL solution). Glass tubes were rinsed twice with 
4 mL of homogenization buffer. Samples were centrifuged at 18,000 × g for 20 min after which the supernatant 
was transferred and centrifuged at 100,000 × g for 67 min at 4 °C. Microsomal pellets were washed with a 125 mM 
phosphate buffer (pH 7.5 containing 1.25 mM EDTA and 20% glycerol, resuspension buffer) and centrifuged 
for a second time at the conditions specified. Afterwards, microsomal pellets were suspended in 0.5 mL/gram 
tissue of resuspension buffer, snap frozen and stored at −80 °C. All procedures were performed on ice.
Hepatic and intestinal microsomal protein concentrations were determined by the Bradford assay57, according 
to the manufacturer’s instructions.
CYP450 quantitative measurement using proteomics. HD-DDA MS experimental set-up. 
Microsomal proteins (20 µg) were reduced in 0.5 M TEABC and 1 mM DTT for 1 hour at 60 °C, followed by alky-
lation using 10 mM MMTS for 10 min at room temperature. Proteins were digested into peptides using trypsin 
(33:1 protein/enzyme ratio; Promega, Wisconsin, USA) overnight at 37 °C with CaCl2 and ACN to a final con-
centration of 1 mM and 5%, respectively. After evaporation in a speedvac, the samples were re-suspended in 0.1% 
formic acid. Four hundred ng sample was spiked with 50 fmol β-galactosidase (Sciex, Washington DC, USA) and 
50 fmol Hi3 Escherichia coli (Waters, Massachusetts, USA) standards before injection. For the intestinal micro-
somes, samples of all sixteen pigs were pooled and measurements were performed in triplicate. Hepatic CYP450 
quantity was determined for each pig.
The peptides were separated using a nanoscale UPLC system (nanoAcquityUPLC, Waters, Milford, USA) 
coupled to a HRMS Q-TOF Synapt G2-Si mass spectrometer (Waters, Massachusetts, USA). Peptides were first 
trapped in 0.1% formic acid on a 180 µm × 20 mm C18 Trap column. Separation was performed on a HSS C18 
1.8 µm, 75 µm × 250 mm analytical column at a flow rate of 300 nL/min and a temperature of 45 °C. Mobile phase 
A and B were composed of 0.1% formic acid with 4% DMSO in UPLC-water and 80% ACN containing 0.1% for-
mic acid, respectively. Peptides were separated with a linear gradient for 60 min at 1–40% solvent B and for 1 min 
at 40–85% solvent B. The HRMS instrument was operated in positive mode for High Definition-DDA, using a 
nano-ESI source, acquiring full scan MS and MS/MS spectra (m/z at 50–5,000) in resolution mode. Survey MS 
scans were acquired using a fixed scan time of 200 ms. Tandem mass spectra of up to eight precursor ions with 
charge state 2+ to 5+ were generated using CID in the trapping region with intensity threshold set at 3,000 cps, 
using a collision energy ramp from 6/9 V (low mass, start/end) up to 147/183 V (high mass, start/end). MS/MS 
scan time was set to 100 ms with an accumulated ion count ‘TIC stop parameter’ of 100,000 cps allowing a maxi-
mum accumulation time of 250 ms. Dynamic exclusion of fragmented precursor ions was set to 12 s. Ion mobility 
spectrometry wave velocity was ramped from 2,500 to 400 m/s. Wideband enhancement was used to obtain a 
near-100% duty cycle on singly-charged fragment ions. LockSpray of glufibrinopeptide-B (m/z 785.8427) was 
acquired at a scan frequency of 60 s.
Data-analysis. Data analysis of the raw files obtained from the Synapt G2-Si was performed in Progenesis® QI 
(Nonlinear Dynamics) version 2.3. Peptides with charge +1 were discarded. For relative quantification, data was 
normalized to all proteins. For absolute quantification, data was normalized to Hi3 E. coli peptides. Peptide iden-
tification was performed with Mascot 2.5, the following search criteria were set: trypsin as digestion enzyme, up 
to two missed cleavages allowed, fixed modification of methylthiocysteine and variable modifications of methio-
nine oxidation and deamidation at asparagine and glutamine. Peptide mass tolerance was set to 15 ppm and 
fragment mass tolerance to 0.2 Da. Protein identifications were obtained by searching a compiled database of 
reviewed Sus Scrofa entries (Swissprot), supplemented with unreviewed CYP proteins and fragments of interest, 
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the cRAP database (laboratory proteins and dust/contact proteins, http://www.thegpm.org/crap/), and sequences 
of spiked standard proteins. For relative quantification, the top three peptides were used and only proteins with 
at least one unique peptide were further considered. For absolute quantification, proteins were quantified using 
the top three peptides against Hi3 E. coli peptides, and only proteins with at least one unique peptide were further 
considered. Although it is hard to assume that the ionization efficiency is the same for each peptide and in each 
sample, this method has been proven reproducible (10% CV) and accurate (15% relative error) for the purpose of 
comparison58. Protein data was exported from Progenesis® for further statistical analysis. For the calculations of 
relative quantity of drug metabolizing CYP450, the mean quantity of each enzyme was calculated as the percent-
age of the mean total detected drug metabolizing enzyme.
CYP450 enzyme activity measurements and inhibition experiments. Activity measure-
ments. Hepatic microsomes were incubated at 37 °C with TB, CZ, MDZ, CM, DXM, and PH at six different 
concentrations (Table 1). The incubation times were derived from linearity experiments. Incubation were per-
formed with different protein concentrations (0.1, 0.25, 0.5, and 0.75 mg/mL) and incubation times (5, 10, 20, 30, 
and 45 min) to determine the linear biotransformation area (data not shown). The substrate concentrations used 
were 100 µM, 20 µM, 1 µM, 20 µM, 5 µM, and 5 µM for TB, CZ, CM, PH, MDZ, and DXM respectively. Protein 
concentrations and time were chosen at the lowest possible value to allow reliable quantification, within the linear 
range of the biotransformation reaction.
After the specified incubation time, an aliquot of 200 µL was transferred to an Eppendorf tube containing 
125 µL of ice cold stop reagent. Samples of the same animal, incubated with different probes, were pooled for each 
concentration and 125 µL of TFA was added. Subsequently, samples were centrifuged for 10 min at 16,200 × g 
at 4 °C. Following centrifugation, the supernatant was transferred to 15 mL conical tubes containing 1 mL of 
a 100 mM phosphate buffer. Next, 7 mL of ethylacetate was added and samples were extracted for 15 min on 
an overhead shaker (IKA® TRAYSTER, Staufen, Germany). The two phases were separated by centrifuging at 
14,000 × g for 5 min. The organic phase was transferred and evaporated at 40 ± 5 °C under a gentle nitrogen 
stream. Samples were reconstituted in 200 µL of a 50/50 methanol/water solution and analyzed by LC-MS/MS as 
previously described59.
Intestinal microsomes were incubated as described above for hepatic microsomes. The final microsomal pro-
tein concentration was 0.75 mg/mL and incubation time was 10 min for all of the probe reactions. Each activ-
ity measurement (hepatic and intestinal) was performed in triplicate and data are presented as mean of these 
replicates.
Michaelis-Menten, Hill kinetics, and Eadie-Hofstee plots. The activity data were fitted against the standard 
Michaelis-Menten equation (Eq. (1a), first term). For each profile, Eadie-Hofstee plots were derived to inves-
tigate involvement of more than one enzyme or deviation from normal Michaelis-Menten behaviour. If the 
Eadie-Hofstee plot was hyperbolic, the data was fitted against the Hill equation60. Km, Vmax and/or Hill coefficients 
were derived for each substrate and pig, in order to obtain the inter-individual variation.
Incubation with inhibitors and two substrates. To assess the selectivity of the probes, incubation with human spe-
cific CYP450 inhibitors was performed. The inhibitors used were α-NFV, 8-MPS, KET, SFZ, QND, and DDC for 
CYP1A/2 A, CYP2A, CYP3A, CYP2C, CYP2D, and CYP2E1, respectively. Each inhibitor was evaluated with its 
corresponding substrate at concentrations around the Km value (20 µM, 1 µM, 20 µM, 200 µM, 10 µM and 50 µM 
for PH, CM, MDZ, TB, DXM and CZ, respectively). Considering the goal of this study, the concentrations of 
inhibitors were chosen to be 0.1 µM, 1 µM, 0.3 µM, 0.5 µM, 0.1 µM and 20 µM for α-NFV, 8-MPS, KET, SFZ, QND, 
and DDC respectively (Supplementary Table 4). These values correspond to the Ki values towards human CYP450 
orthologues, assuming relative similar inhibition for human and porcine CYP450 orthologues. All incubations 
were performed in triplicate.
Second, two substrates were incubated simultaneously to investigate their influence on each other’s biotrans-
formation rate. For the dual substrate incubation experiment, each possible combination of two substrates was 
investigated and incubated at concentrations around or below the Km value. All incubations were performed 
in triplicate. From these experiments, rate ratios were calculated as Rate(substrate + inhibitor)/Rate(control) and Rate(dual 
substrate)/Rate(control). The incubations with inhibitors and two substrates were only performed on porcine hepatic 








Concentration range (µM) (6 
levels)
Tolbutamide CYP2C 0.25 10 5.00–10.0–50.0–100–200–400
Chlorzoxazone CYP2E 0.1 5 2.50–5.00–25.0–50.0–100–200
Coumarin CYP2A 0.1 5 0.25–0.50–2.00–5.00–20.0–100
Phenacetin CYP1A 0.1 5 1.00–5.00–20.0–50.0–100–200
Midazolam CYP3A 0.1 5 0.50–2.00–5.00–10.0–20.0–50.0
Dextromethorphan CYP2D 0.1 5 0.10–0.50–1.00–5.00–20.0–100
Table 1. Incubation conditions for the establishment of concentration-activity profiles in porcine hepatic 
microsomes.
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Selectivity assessment of probes towards porcine CYP450. First, Eadie-Hofstee plots were exam-
ined for deviations from linearity. Biphasic plots are indicative of multiple enzyme involvement or of the pres-
ence of multiple binding sites within the enzyme. Furthermore, correlations between substrate-enzyme and 
substrate-substrate were analyzed to investigate changes in explained variability. In essence, at a fixed concen-
tration, enzyme kinetics can be approximated by a linear function of enzyme concentration(s) (Eqs (1a–d)). 
Changes in correlation coefficients are therefore a reflection of a changing contribution of the enzyme(s) involved 
in the biotransformation.
Second, to identify CYP450 enzymes involved in the biotransformation, stepwise multiple linear regres-
sion was performed. For each typical reaction, the activity data at low concentrations (2nd lowest concentration, 
Table 1) and high concentration (highest concentration, Table 1) were set as the dependent variable to make a 
qualitative distinction between low and high affinity CYP450 enzymes. Independent variables were CYP450 pro-
tein concentrations as measured by the HRMS method. The criterion for inclusion of the independent variable 
in the model was a probability of the F-statistic <0.1, while the criterion for exclusion was a probability of the 
F-statistic >0.2. This approach can be rationalized by assuming that theoretically the Michaelis-Menten constant, 
Km, is a constant over all individuals. This assumption is reasonable as no polymorphisms are known to date that 
affect the intrinsic clearance of substrate drugs15,44. Nevertheless, it should be noted that one polymorphism (1423 
G- > A) in porcine CYP2E1 can lead to a decrease in protein expression61. However, it remains unclear if this 
polymorphism results in the alteration of the enzyme’s metabolic properties due to conflicting results62,63. Given 
this and a fixed concentration for each reaction, the Michaelis-Menten equation (Eq. (1a)) can be reduced to the 
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Where dv/dt, Vmax, Km, kcat, θ, [E], and [S] are the reaction rate, maximal reaction rate, Michaelis-Menten con-
stant, catalytic constant, linear coefficients, enzyme concentration, and substrate concentration respectively. 
Using the same approach, activity data of the substrates were used as independent variables in a second stepwise 
multiple linear regression analysis. This approach can be rationalized by assuming that two probes, which are 
metabolized by the same enzyme, will show a strong correlation and thus explain each other’s variability. Only 
variables associated with positive coefficients, were retained for further investigation.
Since enzymes can be highly correlated due to co-regulation, collinearity was an anticipated problem. To con-
trol the collinearity and thus the stability of the regression, independent variables were standardized. Tolerance 
values were examined and variables with values below 0.3 were considered for further investigation, in addition 
to the variables included in the model. Variables selected this way will be named collinear enzymes or collinear 
metabolites.
Third, inhibition of the substrates on each other’s biotransformation rate was investigated to detect shared 
enzymes. Since most of the substrates and/or their metabolites will inhibit a reaction to a certain extent and tak-
ing into account the accuracy of the used quantification method, which has bounds between −20% and +10%, 
an inhibition of at least 20% was deemed relevant.
Fourth, typical inhibitors for each of the reactions were included at previously reported Ki values43,64. The 
same boundaries were applied as for the dual substrate incubations, i.e. an inhibition of at least 20% was consid-
ered relevant. Finally, activities in the intestinal microsomes were compared to the activities observed in hepatic 
microsomes. Eadie-Hofstee plots were derived as described for hepatic microsomes and profiles were compared. 
Activity ratios (Vmax_intestine/Vmax_liver) were calculated and used to assess enzyme involvement.
Statistical analysis. Stepwise linear regression, correlation analyses, and independent sample t-tests were 
performed with the SPSS® 24 software (IBM, New York, USA). Sex differences in hepatic protein abundances, 
Km, and Vmax values, were analyzed by an independent sample t-test. Normality was checked using the Shapiro 
Wilk test. If the Shapiro Wilk test statistic was significant, log transformation was used to calculate the t-statistic. 
Equality of variances was checked using the Levene’s test for equality of variances. The appropriate test statistic 
was used depending on the equality of variances.
Ethical approval.  All procedures followed were in accordance to the ethical standards of the ethical 
committee of the Faculties of Veterinary Medicine and Bioscience Engineering of Ghent University (approval 
EC2015_213).
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Results
Hepatic and intestinal CYP450 quantitative analysis. The entry information, which provides the 
associated accession number(s), of the detected and quantified enzymes, are shown in Supplementary Table 1. 
The relative quantity of each enzyme is shown in Fig. 1, along with the relative quantity of the human isoforms. 
Mean amount of hepatic drug metabolizing CYP450 enzymes was 365.3 ± 27.41 pmol/mg protein, and for duode-
nal CYP450 3.44 ± 2.42 pmol/mg protein. In the jejunum and ileum, CYP450 were below the UPLC-HRMS limits 
of detection. The identified enzymes in the duodenum belong to the CYP2C and CYP3A subfamilies. No enzymes 
of other subfamilies, i.e. CYP1A, CYP2A, CYP2D and CYP2E were observed. No evidence for sex differences 
were noted for hepatic enzymes (minimum p-value = 0.309 for CYP3A29).
Hepatic and intestinal CYP450 activity and inhibition. Hepatic and intestinal CYP450 activi-
ties. Mean values for Michaelis-Menten parameters of hepatic CYP450 of 8 male and 8 female conventional 
pigs, 12 weeks of age are shown in Table 2. Michaelis-Menten plots can be found in the Supplementary Files. No 
evidence for sex differences was observed in Km and Vmax (minimum p-value for Km = 0.115 (TB) and for Vmax 
p = 0.192 (DXM)), which is reflected in the CYP450 quantities. Consequently, the parameters provided in Table 2 
represent the combined means for male and female pigs.
A hyperbolic Eadie-Hofstee plot for MDZ (CYP3A) was observed (Fig. 2), indicative for auto-activation or 
Hill kinetics60. The Eadie-Hofstee plots for CZ, PH, and TB indicate deviation from standard Michaelis-Menten 
kinetics. Chlorzoxazone and PH are biphasic, while TB does not saturate in the range of TB concentrations tested. 
A Michaelis-Menten equation with two contributing enzymes was fit to the CZ and PH data, but the estimates 
obtained were inaccurate and not significant. However, a fit to a single enzyme kinetic equation resulted in an 
adequate fit (Supplementary Fig. 1). For TB, however, the obtained parameters should be interpreted with care as 
they are estimated without observing saturation due to limitations in the TB solubility.
For the intestinal CYP450, a gradual decrease in Vmax was observed with duodenum > jejunum > ileum. No 
CM-hydroxylase activity could be detected in the intestine and only MDZ-hydroxylase and PH-O-deethylase 
activity were observed over all three segments (Table 3). Duodenal biotransformation of CZ, DXM, and MDZ 
(Fig. 3) displayed Hill kinetics and was consequently fitted against the Hill function.
Intestinal CYP3A and CYP2C activity were much lower as would be expected from enzyme quantity ratios in 
hepatic versus intestinal microsomes. Ratios of CYP3A and CYP2C enzymes (hepatic/duodenal) were 3 and 10 
respectively. However, Vmax of MDZ-hydroxylation and TB-hydroxylation in intestinal microsomes were only 2% 
of the hepatic Vmax values.
Figure 1. Relative amounts of hepatic (a) and duodenal (b) CYP450 proteins in conventional pigs and humans 
(c,d respectively) Total detected hepatic CYP450 was 365.3 ± 27.41 pmol/mg protein (n = 16; age 12 weeks, 8 
males and 8 females), total detected duodenal CYP450 was 3.44 ± 2.42 pmol/mg protein (n = 3, pool of 16 pigs; 
8 males and 8 females). Data for human CYP450 pie charts are derived from43,76,87,88.
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Inhibition of hepatic CYP450 by substrates and inhibitors. Results of the incubation with substrate-inhibitor and 
dual substrates are presented in Tables 4 and 5. In general, TB, CM and DXM had only a limited influence on the 
biotransformation of other substrates (inhibition <20%). In contrast, MDZ decreased almost every other activity 
except for CZ, which showed an increased rate. Furthermore, CZ and PH reduced the CM-hydroxylation, while 
CM did not decrease the CZ-hydroxylation and PH-O-deethylation to the same extent, even though CM has a 
much lower affinity.
Sulphaphenazole and QND did not inhibit any of the investigated reactions, even if the concentration was 
increased to 10 times the concentration described in the materials and methods section. α-Naphthoflavone 
did not inhibit any reaction at a concentration around the Ki value for the human CYP1A2 enzyme (0.1 µM). 
However, when the concentration was increased to 1 µM, PH-O-deethylation (CYP1A2) activity decreased to 
76% of the control value (Table 4). No other reactions were significantly inhibited by α-NFV at this concentration 
(maximal inhibition of 4% for CM).
At a concentration of 20 µM, DDC decreased the TB, CZ and CM hydroxylation. When the concentration 
was increased, all reactions were decreased by >40%. This indicates that DDC has no selectivity for the porcine 
CYP2E1 enzyme and thus cannot be used to draw conclusions about CYP2E1 enzyme involvement.
Ketoconazole and 8-MPS were found to be potent inhibitors of MDZ and CM-hydroxylation, respec-
tively. However, KET could also inhibit TB-hydroxylation and 8-MPS inhibited CZ-hydroxylation and 
PH-O-deethylation, suggesting that either the inhibitors are not selective for CYP3A and CYP2A respectively 
or that the substrates are metabolized by CYP3A (TB) or CYP2A (CZ, PH). Notable is the apparent increase of 
MDZ-hydroxylation observed with all inhibitors, except KET.
Selectivity assessment. Eadie-Hofstee plots of hepatic and intestinal CYP450 activities are dis-
played in Figs 2 and 3. Correlation matrices between activity-enzyme and dual substrates can be found in the 
Supplementary Tables 2 and 3. Of note are the gradual increase or decrease in correlation coefficients as a func-
tion of concentration. Enzymes and metabolites selected by regression analysis can be found in Table 6. A general 
decision tree with associated outcome is given in Fig. 4. Detailed decision trees for each individual substrate are 
given in Supplementary Figs 3–8.
Discussion
To the best of our knowledge, this is the first study to quantify and characterize porcine intestinal CYP450 
enzymes. Duodenal relative quantitative results are remarkably similar between pigs and men, with CYP3A 
constituting 88% and CYP2C 12% of the detected CYP450 enzymes in pigs vs. 82% CYP3A and 16% CYP2C 
in humans (Fig. 1)65. However, intestinal CYP450 activity is much lower in porcine microsomes, espe-
cially for CYP3A, which is 6–40 times lower66,67. In contrast to the Vmax of MDZ-hydroxylation, the Vmax for 
TB-hydroxylation (CYP2C) is similar to those observed in humans67, although direct comparison is difficult due 
to the different amounts of intestinal sample used for microsomes preparation. Hence no systematic comparison 
could be performed. In the current study, intestinal pieces of 4 grams were processed, while in previous studies66,67 
mucosal scrapings of 1 foot sections or entire gut length were used. Likewise, the observed discrepancy for the 
CYP3A activity, can be attributed in part to the difference in intestinal microsomes preparation. Previously it has 
been shown that the elution of intestinal samples with EDTA resulted in the highest CYP450 activity when com-
pared to the mucosal scraping method68. Furthermore, in the comparison between the EDTA elution method and 
the mincing method, it was shown that the latter resulted in higher enzymatic activities and more reproducible 
results69. Hence the mincing method was used in the current study.
The current study shows that the total detected amount of hepatic CYP450 enzymes is similar between pigs 
and humans (365 vs. 240–303 pmol/mg protein)70,71. Relative amounts of porcine hepatic CYP450 enzymes 
are in agreement with the results of Achour et al. (2011). They investigated the CYP450 quantity in two adult 
conventional pigs, with a maximal difference of 5% in relative quantity for CYP2E1 compared to the current 
study. No evidence for sex differences was found, which corresponds with the recent results of Millecam et al. 
(2018)72. However, compared to humans, differences in relative quantities are observed, with CYP2C, CYP1A2, 











PH 20.0 (14.88) 1404 (403.6) — 10–50 241–2173 43,81,82
CM 1.3 (0.47) 303 (119.2) — 0.5–2 259–1275 7,10,37,43,92
MDZ 15.3 (4.4) 1848 (637) 1.23 (0.089) 3–9 190–4380 43,48,50,92,93
TBa 2079 (1821) 269 (182.1) — 60–400 66–434 15,43,76,92,94
DXM 6.7 (5.70) 1592 (480.7) — 2.2–8.5 18–233 43,86–88,92
CZ 53.6 (18.39) 764 (259.1) — 39–152 575–2301 10,21,43,45,77,78,92,95,96
Table 2. Michaelis-Menten and Hill parameters for porcine hepatic CYP450 enzymes (8 males, 8 females, 12 
weeks of age, each time 3 replicates). Results are expressed as mean (and standard deviation). Vmax, maximal 
reaction rate; Km, Michaelis-Menten constant; PH, phenacetin; CM, coumarin; MDZ, midazolam; TB, 
tolbutamide; DXM, dextromethorphan; CZ, chlorzoxazone. aFitted coefficients for this compound should be 
interpreted with care as the reaction rate did not reach saturation.
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Figure 2. Eadie-Hofstee plots of CYP450 activity for tolbutamide, chlorzoxazone, coumarin, phenacetin, 
midazolam, and dextromethorphan, in porcine liver (n = 16, 8 males, 8 females, 12 weeks of age).
Duodenum Jejunum Ileum
Vmax (pmol/min/
mg protein) Km (µM) a
Vmax (pmol/min/
mg protein) Km (µM) a
Vmax (pmol/min/
mg protein) Km (µM) a
PH 14.1 (2.14) 143.5 (41.04) na 2.97 (1.221) 181.7 (129.74) na 2.41 (0.684) 188.6 (91.66) na
CM Nd nd nd nd nd nd nd nd nd
MDZ 39.5 (1.47) 22.1 (1.59) 1.26 (0.048) 2.71 (1.411) 23.1 (1.15) 1.41 (0.043) 1.57 (0.025) 16.2 (0.040) 1.56 (0.45)
TB 4.68 (3.383) 1407.5 (1248) na nd nd nd nd nd nd
DXM 2.16 (0.186) 31.5 (8.13) 0.81 (3.873) nd nd nd nd nd nd
CZ 7.64 (0.458) 125.6 (13.18) 1.25 (0.058) nd nd nd nd nd nd
Table 3. Michaelis-Menten and Hill parameters for porcine intestinal CYP450 enzymes (n = 3 replicates of a 
pool of 16 pigs, 8 males and 8 females, 12 weeks of age). Results are expressed as mean (and standard deviation). 
Vmax, maximal reaction rate; Km, Michaelis-Menten constant; a, Hill coefficient; PH, phenacetin; CM, coumarin; 
MDZ, midazolam; TB, tolbutamide; DXM, dextromethorphan; CZ, chlorzoxazone; na, not applicable; nd, not 
detected.
Figure 3. Eadie-Hofstee plots of CYP450 activity for tolbutamide, chlorzoxazone, and dextromethorphan in 
porcine duodenum (DD), and of phenacetin, midazolam in duodenum, jejunum (JJ) and ileum (IL).
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and CYP2A, CYP2D, and CYP2E being more abundant (31 vs. ~7%, 28 vs. ~2%, and 13% vs. 8–17%, in pigs vs 
humans, respectively) (Fig. 1)70,73,74.
The 2.5 times lower quantity of porcine CYP2C enzymes seems to be reflected in the lower TB-hydroxylase 
activity compared to human15. However, it should be mentioned that due to the limited concentration range of 
TB, with no obvious observable saturation of the kinetics, it is recognized that the Km and Vmax estimates reported 
herein can be biased. Nevertheless, previous reported Vmax values in porcine hepatic microsomes range from 
62–440 pmol/mg protein/min15,19,75 which are similar to the values reported here and within the range reported 
for humans. The affinity, on the other hand, is approximately 5 to 10 times lower76. It should be mentioned that 
the Km estimate of tolbutamide differs somewhat from previous experiments by Schelstraete et al. (2018)59. This 
can be attributed to the fact that for the Km estimation in the latter reference, the highest concentration level was 
included. In addition, the microsomes originated from different animals as described in this study.
In contrast to the similar biotransformation, SFZ did not inhibit TB-hydroxylation, indicating some qualita-
tive differences with the human orthologues19. Nevertheless, with respect to the selectivity, the CYP2C enzymes 
were most likely the major contributors to TB-hydroxylation, as they showed strong correlations with the activity. 
Furthermore, TB did not influence the biotransformation of other probes. However, KET could also inhibit the 
reaction moderately, a feature also seen in humans64. Therefore, in addition to the increasing correlations with 
MDZ-hydroxylation and CYP3A46, and biphasic intestinal metabolism, CYP3A enzymes probably contribute to 
a low affinity phase.
The Vmax of the CZ-hydroxylation reaction was similar between porcine and human microsomes (764 vs. 
575–3,100 pmol/min/mg protein)15,77. Remarkably the porcine and human CYP2E1 are almost equally abundant, 
representing 13% and 9% of drug-metabolizing CYP450 respectively70. However, the selectivity of chlorzoxazone 
for CYP2E1 has been questioned43,47,52. In humans, CYP1A2 and CYP3A also contribute to the reaction78–80, 
whereas in pigs recombinant CYP1A1, CYP2A19, and CYP2C33 are able to hydroxylate CZ47.
At low substrate concentrations, CYP3A46 and PAR were selected from the regression analysis. Nonetheless, 
KET could only marginally inhibit CZ-hydroxylation (20%) and α-NFV did not inhibit the reaction. In con-
trast, 8-MPS inhibited the reaction to about 28%. Furthermore, CM, PH, and CZ affected each other’s bio-
transformation significantly, leading to the conclusion that mainly CYP2A19 and CYP1A2 are responsible 
for CZ-biotransformation. Indeed, when combining the CYP450 amounts in microsomes with data from 
recombinantly expressed CYP45047, CYP2A19 and CYP1A2 account for 72% of CZ-hydroxylation at a 5 µM 
concentration.
At higher substrate concentrations, CYP2E1, in addition to CYP2C and CYP3A enzymes, most likely metab-
olize CZ. Even though no marked influence was seen on CZ-hydroxylation by TB or MDZ, the associated parallel 
increase in correlation coefficient between CZ-hydroxylation and CYP3A, CYP2C enzymes at one hand, and 
TB and MDZ on the other hand, in combination with duodenal activity, suggests their involvement. However, 
Wiercinska and Squires expressed recombinant porcine CYP3A, but were unable to detect CZ-hydroxylase 
Subfamily Inhibitor
CYP2C CYP2E CYP2A CYP3A CYP1A CYP2D
TB CZ CM MDZ PH DXM
CYP2C Sulphaphenazole 0.98 (0.135) 1.03 (0.061) 1.05 (0.023) 1.20 (0.050) 1.09 (0.030) 0.97 (0.080)
CYP1A/2A α-naphthoflavone 1.13 (0.099) 1.06 (0.057) 0.94 (0.131) 1.08 (0.048) 0.76 (0.011) 1.02 (0.143)
CYP2D Quinidine 0.97 (0.052) 1.07(0.044) 1.06 (0.072) 1.26 (0.075) 1.15 (0.016) 0.98 (0.080)
CYP3A Ketoconazole 0.68 (0.107) 0.80 (0.011) 0.82 (0.073) 0.22 (0.007) 1.08 (0.066) 0.96 (0.100)
CYP2E Diethyldithiocarbamate 0.87 (0.046) 0.87 (0.003)- 0.74 (0.079) 1.15 (0.074) 1.04 (0.010) 0.93 (0.084)
CYP2A 8-methoxypsoralen 1.01 (0.078) 0.72 (0.044) 0.13 (0.007) 1.29 (0.060) 0.68 (0.026) 0.95 (0.112)
Table 4. Influence of inhibitors at concentrations around their Ki values on different CYP450 enzyme 
activities in porcine hepatic microsomes. Results are presented as ratio of residual activity (reaction rate of 
substrate + inhibitor versus substrate only (control)). Value represents the mean of 3 replicate measurements 
(and standard deviation). TB, tolbutamide; CZ, chlorzoxazone; CM, coumarin; PH, phenacetin; MDZ, 
midazolam; DXM, dextromethorphan.
TB CZ CM PH MDZ DXM
TB — 0.97 (0.026) 0.92 (0.021) 0.88 (0.024) 1.01 (0.031) 0.97 (0.043)
CZ 0.87 (0.014) — 0.57 (0.012) 0.59 (0.006) 0.98 (0.053) 0.93 (0.073)
CM 0.89 (0.043) 0.86 (0.007) — 0.83 (0.020) 0.92 (0.038) 0.99 (0.072)
PH 0.88 (0.033) 0.73 (0.041) 0.55 (0.027) — 0.93 (0.032 0.95 (0.106)
MDZ 0.55 (0.041) 1.23 (0.019) 0.62 (0.027) 0.71 (0.011) — 0.50 (0.034)
DXM 0.82 (0.153) 0.95 (0.050) 0.86 (0.106) 0.82 (0.082) 0.84 (0.115) —
Table 5. Dual substrate incubations in porcine hepatic microsomes. Results are presented as the ratio of the 
reaction rate of dual substrates versus single substrate incubations. The means are presented of 3 replicate 
measurements (and standard deviation). TB, tolbutamide; CZ, chlorzoxazone; CM, coumarin; PH, phenacetin; 
MDZ, midazolam; DXM, dextromethorphan.
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activity from this enzyme47. Of note is that their cloned CYP3A differed 2 amino acids from the detected 
CYP3A29 in this study. Finally, at higher concentrations CYP2E1 was the variable explaining most of the varia-
bility in CZ-hydroxylation, suggesting its role in catalyzing the reaction.
Coumarin is almost exclusively used as CYP2A6 probe43. The CYP2A19 enzyme represents 31% of the 
hepatic CYP450 enzymes with a comparable Vmax value for humans, depending on the reference (Table 2). 
Coumarin-hydroxylation is proposed to be specific in pigs44, indicating that porcine CYP2A19 is less effi-
cient. The current study also shows that coumarin is selective for CYP2A19. However, CM-hydroxylation and 
PH-O-deethylation correlated significantly, indicating a shared enzyme. As a consequence of the strong inhi-
bition by 8-MPS (87%) and weak inhibition of the CYP1A2 associated inhibitor α-NFV (5%), the monophasic 
Eadie-Hofstee plot, and the absence of intestinal biotransformation, CYP2A19 is likely the sole important con-
tributor to CM-hydroxylation.
In contrast, PH, a typical human CYP1A2 probe, is most likely metabolized in part by CYP2A19. This is 
supported by the fact the Vmax of the PH-deethylation is similar (Vmax 1,404 vs 241–217381,82, pig and human), 
although the amount of CYP1A2 is 4 times lower in pigs compared to humans suggesting higher efficiency of 
porcine CYP1A2 or involvement of additional enzymes. Indeed, as PH and CM could affect the other’s bio-
transformation rate, and 8-MPS inhibited PH-O-deethylation, CYP2A19 is likely involved. Hence, CYP2A19 
seems to have broader substrate selectivity compared to human CYP2A6 as indicated by its capability of 
metabolizing PH and CZ. This apparent broader substrate selectivity of CYP2A19 is further supported by a 
Substrate TB CZ CM PH MDZ DXM
Conc Levela 2 5 2 6 2 6 2 6 2 6 2 6
























OH-TB OH-CM OH-TB OH-MDZ
Table 6. Selected enzymes and metabolites by regression analysis. Enzymes and metabolites written in ‘italics’ 
are collinear variables with a tolerance value < 0.3. Criteria for inclusion and exclusion were a F-statistic <0.1 
or >0.2, respectively. TB, tolbutamide; CZ, chlorzoxazone; CM, coumarin; PH, phenacetin; MDZ, midazolam; 
DXM, dextromethorphan; DEX, dextrorphan; OH-CZ, 6-OH-chlorzoxazone; OH-CM, 5-hydroxy-coumarin; 
PAR, paracetamol; OH-TB, 9-OH-tolbutamide; OH-MDZ, 1-OH-midazolam.aConcentration levels are 
specified in Table 1.
Figure 4. General decision tree for enzyme involvement. No distinction is made between enzymes belonging 
to the same subfamily. For a specific flow scheme for each substrate, the reader is referred to the Supplementary 
Data.
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report in which 1-ethoxyresorufin, another frequently used CYP1A2 substrate, was found to markedly affect 
coumarin-hydroxylation when co-incubated83. Finally, α-NFV was able to inhibit PH-O-deethylation (24%), 
indicating that CYP1A2 is involved in its biotransformation.
At higher concentrations, additional enzymes contribute to the PH-deethylation. The observation of a sim-
ilar biphasic plot in hepatic and duodenal microsomes, suggests involvement of CYP2C and CYP3A enzymes, 
although in hepatic microsomes KET could not inhibit PH-O-deethylation at concentrations around the Km value. 
Nevertheless, strong correlations (r = 0.80) were observed between PH-O-deethylation and MDZ-hydroxylation. 
In addition, CM- and CZ-hydroxylation explained most of the PH-O-deethylation variability. Although CZ is not 
very selective for CYP2E1, a parallel increase in correlation with this enzyme suggests CYP2E1 has low affinity for 
PH-deethylation, as observed in humans84.
The MDZ-hydroxylation rate is about 2 to 3 times lower compared to humans48, paralleled by the approxi-
mately 3 times lower amount of CYP3A observed in the current study. Our results indicate that MDZ is largely 
selective for porcine CYP3A. Similar Eadie-Hofstee plots in hepatic and intestinal microsomes indicate the 
involvement of the same enzymes. Remarkably, MDZ reduced all reactions except CZ-hydroxylation, although 
this results possibly from nonselective binding of MDZ or a metabolite thereof, as supported by the observation 
of a sigmoidal profile, a characteristic observed for nonselective binding of other weak bases85. In addition, all 
inhibitors, except KET, enhanced MDZ-hydroxylation, which can be hypothesized to result from an increase in 
free concentration.
It has been shown that rCYP3A22 had the highest intrinsic MDZ clearance, followed by rCYP3A29 and 
rCYP3A4648. CYP3A22 had the highest quantity amongst CYP3A enzymes, which is reflected by the signifi-
cant correlations with MDZ biotransformation at all concentrations. No significant correlation was found for 
CYP3A29, although it has a high intrinsic clearance and is the second highest quantified CYP3A enzyme48. 
A possible explanation is a polymorphism in the CYP3A29 sequence, supported by the existence of a CYP3A 
sequence in the Uniprot database, differing in only two amino acids (Asn423->His, Lys458->Arg). Recently, this 
sequence was recombinantly expressed. Unfortunately no CYP3A substrate was measured47.
Dextromethorphan-O-demethylation was exceptionally high, being up to 7 times faster in pigs than in 
humans (1,593 vs. 18.0–233 pmol/min/mg protein)86–88, which reflects the 14 times higher quantity of CYP2D 
(28% vs. 2% in humans)20,70,89,90. However, porcine DXM-metabolism has been debated with CYP2B22 rather 
than CYP2D25 being responsible for DXM-O-demethylation20,89,90. Nevertheless, no CYP2B22 was observed in 
this study. Hence it is unlikely that CYP2B22 is the most important enzyme in DXM-O-demethylation.
Regression analysis selected CYP3A46, CYP2C33, OH-TB, and OH-MDZ as predictive variables. 
However, KET could not inhibit DXM-O-demethylation and only MDZ had a marked influence, on the 
DXM-biotransformation, although this probably resulted from nonselective binding. As a consequence, these 
enzymes are most likely not the major contributors to the DXM biotransformation. CYP2D25, however, also cor-
related significantly with the DXM-O-demethylation (r = 0.55–0.66). Although QND did not inhibit the reaction, 
in line with other reports20,89, the observed correlation in addition to the high biotransformation rate and linear 
Eadie-Hofstee plot, which is indicative for single enzyme involvement at the used concentrations, suppose that 
CYP2D25 is most likely responsible for DXM-biotransformation.
Conclusions
Tolbutamide, CM, MDZ, and DXM selectivity is similar between pigs and humans. This is an important feature 
for a potential preclinical animal species, as most of the currently available drugs are metabolized by CYP2C, 
CYP3A, and CYP2D. Moreover, being capable of producing the same metabolites at more or less equal rates is 
crucial in the safety and toxicological assessment of new drug candidates, as not only the parent molecule but also 
the metabolites can give rise to safety concerns. In contrast, CZ and PH are metabolized in part by CYP2A19. In 
humans, CZ is not metabolized by CYP2A6 and PH only to a limited extend84,91. This may be due to the higher 
amount and broader substrate-selectivity of CYP2A19. In addition, SFZ and QND showed no inhibition towards 
CYP2C and CYP2D25 respectively, indicating some differences in binding characteristics compared to human 
CYP450 orthologues. To conclude, the results presented herein support the use of the pig as an appropriate ani-
mal species for drug metabolism studies, based on the similarities in selectivity- and quantity- normalized activ-
ities, especially for the most important CYP3A subfamily. The current study provided an important step towards 
a consistent and systematic validation of the pig as a model for human drug metabolism.
Data Availability
All data analyzed during this study are included in the published article and its Supplementary Information Files. 
The raw proteomics data will be made available to one of the public repositories mentioned in the Editorial and 
Publishing policies.
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